Risk of major adverse cardiovascular events and all-cause mortality under treatment with GLP-1 RAs or the dual GIP/GLP-1 receptor agonist tirzepatide in overweight or obese adults without diabetes: a systematic review and meta-analysis - Stefanou, M-, I; Palaiodimou, L; Theodorou, A (Ther Adv Neurol Disord, 2024)
17562864241281903